Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Zai Lab And Novocure Announce Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant And Clinically Meaningful Extension In Overall Survival For Patients With Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

June 6 (Reuters) - Zai Lab Ltd  9688.HK :
    * ZAI LAB AND NOVOCURE ANNOUNCE LUNAR PHASE 3 CLINICAL TRIAL
DEMONSTRATES STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL
EXTENSION IN OVERALL SURVIVAL FOR PATIENTS WITH METASTATIC
NON-SMALL CELL LUNG CANCER AFTER PLATINUM-BASED THERAPIES
    * ZAI LAB LTD - TUMOR TREATING FIELDS THERAPY TOGETHER WITH
IMMUNE
CHECKPOINT INHIBITORS RESULTED IN 8-MONTH IMPROVEMENT IN MEDIAN
OVERALL SURVIVAL

Source text for Eikon:  ID:nGNX8lmBLv 
Further company coverage:  9688.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zai Lab

See all news